Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Treatment-Resistant Schizophrenia
NCT03983018Phase 2Completed
- Sponsor
- Region Örebro län
- Start
- Aug 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in schizophrenia spectrum and other psychotic disorders, sponsored by Region Örebro län. Started Aug 2019; status: completed.
02
Drugs
rituximab
03
Conditions
schizophrenia spectrum and other psychotic disorders
Beyond the preview
Go deeper on NCT03983018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983018.